NovoTTF-100A: a new treatment modality for recurrent glioblastoma. Expert Rev Neurother 2012 Aug;12(8):895-9
Date
06/20/2012Pubmed ID
22708931DOI
10.1586/ern.12.80Scopus ID
2-s2.0-84866640709 (requires institutional sign-in at Scopus site) 57 CitationsAbstract
NovoTTF-100A (Novocure Inc., Haifa, Israel) is a first-of-a-kind device approved by the US FDA for the treatment of recurrent glioblastoma. It works by emitting a low-intensity, intermediate-frequency (200 kHz), alternating electric field administered via insulated transducer arrays applied onto the scalp. The electric field penetrates the brain and inhibits the growth and proliferation of glioblastoma by interfering with tumor cell mitosis at anaphase. Results from a Phase III clinical trial indicate that the efficacy of NovoTTF-100A is equivalent to standard-of-care chemotherapy. The side effect profile favors device-treated patients, obviating typical toxicities associated with chemotherapy or targeted drugs, and results in improvements in their quality of life. NovoTTF-100A is a new modality of cancer treatment that offers equivalent efficacy, but less toxicity, to recurrent glioblastoma patients when compared with existing treatments.
Author List
Fonkem E, Wong ETAuthor
Ekokobe Fonkem DO Chair, Professor in the Neurology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnaphaseAntineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Brain Neoplasms
Clinical Trials, Phase III as Topic
Electric Stimulation Therapy
Glioblastoma
Humans
Neoplasm Recurrence, Local
Quality of Life
Scalp
Therapeutic Equivalency
